

Promoting Innovation and Delivery of Cell and Gene Therapies

A Virtual Educational Briefing

April 28, 2022 | 11:30 a.m. ET

The U.S. Food and Drug Administration [anticipates](#) a promising but challenging upswing in investigational new drug applications for cell and gene therapy products in the next five years. By addressing the root causes of disease for millions of American patients living with certain cancers and genetically based rare diseases, cell and gene therapies promise to mitigate the suffering and costs associated with the continued progression of their conditions. To take full advantage of this growing pipeline of new treatments, however, it will be important to adopt public policies designed to alleviate the regulatory, reimbursement, and clinical adoption challenges that make it difficult for clinicians and patients to access these therapies.

It is in this context that the co-chairs of the Congressional Personalized Medicine Caucus, in cooperation with the Personalized Medicine Coalition, a nonprofit education and advocacy organization, organized *Promoting Innovation and Delivery of Cell and Gene Therapies*, a virtual educational briefing that took place on April 28, 2022.

- [Video Recording: Promoting Innovation and Delivery of Cell and Gene Therapies](#)

Featuring remarks from three of the caucus co-chairs, Rep. Eric Swalwell (D-CA), Rep. Tom Emmer (R-MN), and Senator Tim Scott (R-SC), as well as discussions between patient, payer and industry representatives, *Promoting Innovation and Delivery of Cell and Gene Therapies* underlined the urgent need for solutions designed to ensure that potentially curative forthcoming therapies for cancer and rare diseases are accessible to patients who need them as soon as they come to market.

A list of speakers featured during the briefing is appended. For more information about the Congressional Personalized Medicine Caucus, please contact Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition, at cbens@personalizedmedicinecoalition.org.

About the Congressional Personalized Medicine Caucus

The [Congressional Personalized Medicine Caucus](#) is a bicameral, bipartisan forum that seeks to engage members of Congress in a constructive dialogue on legislative and regulatory policies that can help realize the full potential of personalized medicine. Sens. Tim Scott (R-SC) and Kyrsten Sinema (D-AZ) and Reps. Eric Swalwell (D-CA) and Tom Emmer (R-MN) serve as the co-chairs of the caucus.

Featured Speakers



MODERATOR

Cynthia A. Bens

Senior Vice President, Public Policy
Personalized Medicine Coalition



Stephanie A. Dyson, R.N., M.A.

Vice President, Head of U.S. Policy & Government Affairs
Bristol Myers Squibb



Brian Koffman, M.D.C.M., M.S. Ed.

Co-Founder, Executive Vice President, Chief Medical Officer
CLL Society
chronic lymphocytic leukemia patient who benefited from
CAR-T therapy



Michael Sherman, M.D., M.B.A., M.S.

Executive Vice President, Chief Medical Officer
Point32Health



Ashley Valentine

Co-Founder, President
Sick Cells



Lowell M. Zeta

Partner
Hogan Lovells
formerly Senior Counselor to U.S. Food and Drug
Administration Commissioner